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Abstract: Sonic hedgehog (Shh) pathway impairment plays a key role in the pathogenesis of basal-cell carcinomas 
(BCC), the most frequent skin tumor among Caucasians. Shh, Smo, and Gli2 family proteins are necessary for 
adequate and controlled cell proliferation. The aim of this study was to evaluate Shh, Smo, and Smo expression 
in BCC skin biopsies taken from sun-exposed areas. 41 BCC skin biopsies and 22 healthy skin specimens (the 
control group) taken from the same areas served as material for the study. All specimens were immunohisto-
chemically stained with monoclonal antibodies directed against the chosen proteins. Shh and Smo expression 
(cytoplasmic pattern) were recorded semiquantitatively using a four-grade score (0–3). Gli2 expression (nuclear 
pattern) was determined using an image analysis system (semiautomatic function). The immunoexpression of 
the Shh and Smo proteins significantly increased in the BCC group, as compared with the normal controls (for 
Shh, the mean intensity was 1.67 in BCC vs. 1.17 in the control group, p < 0.001; for Smo, the mean intensity 
was 1.46 in BCC vs. 0.99 in the control group, p < 0.001). The staining for Gli2 in the BCC group was completely 
negative, but indicated the presence of Gli2 in the control patients (1.15 Gli2+ cells/100 cells). Sonic hedgehog 
pathway dysregulation may play an important role in skin cancerogenesis leading to BCC development. (Folia 
Histochemica et Cytobiologica 2013, Vol. 51, No. 3, 219–224)
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Introduction
Basal-cell carcinoma (BCC) is the most frequent skin 
cancer among Caucasians, as well as the most com-
mon of all human cancers. Recently, there has been 
a significant increase in the incidence of BCC, espe-
cially among women [1]. BCC is generally a disorder of 
white individuals, arising particularly in sun-exposed 
body areas, most commonly on the head and neck, 
but also on the trunk and extremities [2].
The development of BCC is clearly associated with 
ionizing radiation, arsenic, and ultraviolet radiation, 
the last of which is the most important environmen-
tal risk factor. Epidemiological studies have shown 
that BCC risk correlates better with intermittent sun 
exposure than with cumulative lifetime sun exposure 
[3]. Short-wavelength UVB radiation (290–320 nm) 
has been shown to play the most significant role in 
BCC carcinogenesis. UVB radiation damages DNA 
and its repair system and alters the immune system, 
resulting in progressive genetic alterations and the 
formation of neoplasms. Experimental data indicate 
that a range of mutations is caused by UV radiation, 
one of which activates the hedgehog intercellular 
signaling pathway genes [4]. 
The hedgehog signaling pathway was first de-
scribed in genetic studies of embryonic mutants of 
the fruit fly Drosophila melanogaster. Fruit flies have 
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a single HH gene, whereas vertebrates have evolved 
three different types of homolog — the Sonic, Desert, 
and Indian types [4]. Among these, sonic hedgehog 
(Shh) is the most commonly expressed and the best 
characterized in embryonic and adult tissues [5, 6]. 
Under physiological conditions, the sonic hedgehog 
pathway is responsible for normal embryogenesis, for 
regeneration of damaged tissues, and for regulation 
of cell proliferation [7]. Recent studies indicate that 
up-regulation of the Shh pathway may lead to the 
development of tumors in tissues of different ori-
gin—chiefly BCCs in the skin, medulloblastomas and 
gliomas in the brain, and rhabdosarcomas in muscle 
[8–10]. Mutations in the Shh signaling pathway are 
also involved in digestive tract, pancreatic, and small-
cell lung cancers [8, 11–13].
Shh is synthesized as a 45 kDa precursor, which 
activates the Shh signaling pathway by binding to 
the membrane receptor Patched (Ptch), which is 
a 12-pass transmembrane protein. After binding the 
sonic hedgehog protein Shh to the Ptch receptor, 
Smo protein is released and acts as transcriptional 
activator through the Gli nuclear factor, which moves 
from cytoplasm to nucleus. This results in controlled 
cell proliferation and differentiation through the 
activation of target genes.
It is important to note that UV radiation causes an 
inactivated mutation in the PTCH gene. These events 
lead to dysregulation of the sonic hedgehog pathway 
by activating the Smo protein and the Gli transcriptio-
nal factors, which stimulate cell proliferation. In 
consequence, this may lead to the development of 
BCC, for which UV radiation is the major risk factor. 
The aim of this study was to assess the immuno-
expression of the Shh, Smo, and Gli2 proteins in the 
nodular form of BCC localized on UV-exposed areas, 
compared with normal epidermis. Additionally, the 
correlations between the immunoexpression of Shh 
and Smo, as well as between Gli2 in the BCC group 
and the control group, were analyzed.
Material and methods
Patients. The study group consisted of 41 patients with BCC 
(mean age 59.2 years, 20 F, 21 M, phototype: I/II —10, III 
—23, IV — 8), diagnosed in the Department of Dermato-
logy at the Medical University of Lodz between 2008 and 
2010. All patients were Caucasian; none of them were organ 
transplant recipients, were being treated with immuno-
suppressive drugs, or suffered from any other malignancy. 
The patients were recruited at first attendance, when the 
biopsy for histology was taken. Skin biopsies for immunohi-
stochemistry were taken during the second visit, when the 
diagnosis had been confirmed by histology (approximately 
2 weeks after the first visit). Only patients with nodular BCC 
located in the upper cheek area were included. Additio-
nally, 22 age- and sex-matched healthy subjects (mean age 
55.3 years, 12 F, 10 M, phototype I/II — 4, III — 15, IV — 3) 
were enrolled to serve as a control group. Skin specimens 
in the control group were taken from the same areas as in 
the BCC group. Each subject gave written informed consent 
before entering the study, which had been approved by 
the local Ethics Committee. The subjects were assessed by 
a dermatologist for their skin phototype, according to the 
Fitzpatrick score, and for hair and eye color. The tissues 
were immediately snap-frozen in liquid nitrogen and stored 
at –80°C until analysis. 
Immunohistochemistry. Paraffin-embedded tissue sections 
were mounted onto SuperFrost slides, deparaffinized, and 
treated in a microwave oven in a solution of TRS (Target 
Retrieval Solution, Dako, Glostrup, Denmark) for 30 minu-
tes (2 × 6 minutes at 360W, 2 × 5 at 180W, 2 × 4 minutes at 
90W), and were transferred to distilled water. Endogenous 
peroxidase activity was blocked using 0.3% hydrogen peroxi-
de in distilled water for 30 minutes, and then sections were 
rinsed with Tris-buffered saline (TBS, Dako) and incubated 
for one hour with primary rabbit polyclonal antibody against 
Shh (ab 73958, dilution 1:100, Abcam, Cambridge, MA, 
USA), Smo (Abcam ab 72130, concentration 10 µg/mL), and 
Gli2 (Abcam ab 26056; concentration 6 µg/mL) proteins. 
Immunoreactive proteins were visualized using an EnVision 
horseradish peroxidase kit (Dako, Carpinteria, CA, USA), 
according to the instructions of the manufacturer. Visualiza-
tion was performed by incubating the sections in a solution 
of 3,3’-diaminobenzidine (DakoCytomation, Glostrup, 
Denmark). After washing, the sections were counterstained 
with hematoxylin and coverslipped. For each antibody and 
for each sample, a negative control was processed. Negative 
controls were carried out by incubation in the absence of 
the primary antibody, and always yielded negative results.
In each specimen, the staining intensities of Shh and Smo 
were recorded semiquantitatively using two independent 
observers in 7–10 adjacent high-power fields, and graded 
from 0 (staining not detectable), 1 (weak immunostaining), 
2 (moderate immunostaining intensity) and 3 (strong sta-
ining). The mean grade was calculated by averaging the 
grades assigned by two of the authors and approximating 
the arithmetical mean to the nearest unity.
Morphometry. Histological morphometry was performed 
using an image-analysis system consisting of a personal 
computer equipped with a Pentagram graphical tablet, an 
Indeo Fast card (frame grabber, true-color, real-time; Indeo, 
Taipei, Taiwan), and a color TV camera (Panasonic, Tokyo, 
Japan) coupled to a Carl Zeiss Jenaval microscope (Carl 
Zeiss, Jena, Germany). This system was programmed (Mul-
tiScan 8.08 software, Computer Scanning Systems, Warsaw, 
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Poland) to calculate the number of objects (semiautomatic 
function), as has been previously described [14]. 
In brief, the colored microscopic images were saved 
serially in the memory of a computer, and the percentage 
of nuclei expressing the Gli2 antigen was estimated semi
-automatically by counting 100 cells on ten monitor fields 
(0.0205 mm2 each). Immunopositive cells were marked, so 
that in each case, 1000 cells were analyzed. 
Statistical analysis. All values were expressed as mean ± SD 
(standard deviation). The differences between groups were 
tested using Student’s t-test for independent samples, prece-
ded by evaluation of normality and homogeneity of variances 
using Levene’s test. Additionally the Mann-Whitney U-test 
was employed where appropriate. Correlation coefficients 
were calculated using Spearman’s method. The results were 
considered statistically significant when p < 0.05. 
Results
In the basal-cell carcinoma (BCC) group, staining 
for Shh was positive in 34 of 41 patients; for Smo, 
in 32 of 41 participants. Both Shh and Smo proteins 
were detected in some, though not all, cancer cells 
(Figures 1A, 2A, 3A, and 4A) and, in a few cases, on 
inflammatory infiltrates. However, for the present 
study, the staining on inflammatory cells was not ta-
ken into consideration. In the controls, weak staining 
for Shh was positive in 16 of 22 cases; for Smo, in 
14 of 22 specimens. The immunoexpression of Shh 
and Smo proteins was found in the keratinocytes 
(Figures 1B, 2B, 3B, and 4B) of normal epidermis. 
No reactivity was found in sebaceous glands for these 
proteins. Shh immunoexpression was detected in the 
cytoplasm, Smo was expressed in both the cytoplasm 
and cell membrane, and Gli2 immunoexpression was 
exclusively nuclear in epithelial cells. Sporadic Gli2 
immunoexpression on inflammatory infiltrates was 
not taken into consideration. The semiquantitative 
and morphometric data for the immunoexpression 
of Shh, Smo, and Gli2 in BCC and the control group 
are given in Table 1. The immunoexpression of the 
Shh and Smo proteins was significantly increased in 
the BCC group, as compared to the normal controls. 
The staining for Gli2 in BCC group was completely 
negative, (Figures 5A and 6A) but Gli2 was detected 
in the control patients (Figures 5B and 6B).
The correlations between the immunoexpression 
of Shh and Smo, as well as between Gli2 in basal-cell 
carcinoma and the controls, are shown in Table 2. The 
immunoexpression of Shh was significantly positively cor-
related with the immunoexpression of Smo in both tested 
groups. In the controls, the immunoexpression of Shh 
tended to be positively correlated with staining for Gli2, 
but this correlation did not reach statistical significance. 
Discussion
The pathogenesis of BCC development has been 
widely analyzed in recent years. Many scientific 
communications indicate that the pivotal molecular 
abnormality in BCC carcinogenesis is the inappropria-
A B
Figure 1. Immunoexpression of Shh in BCC cells (A) and in 
normal epidermis (B). × 100
A B
Figure 2. Immunoexpression of Shh in BCC cells (A) and in 
normal epidermis (B). × 100
BA
Figure 3. Immunoexpression of Smo in several BCC cells 
(A) and in normal epidermis (B). × 100
Figure 4. Immunoexpression of Smo in several BCC cells 
(A) and in normal epidermis (B). × 400
A B
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te activation of the Shh signaling pathway. Ling et al. 
[15], as well as Xie et al. [16], have reported that more 
than 70% of sporadic BCCs have detectable genetic 
mutations in components of the Shh signaling pathway. 
In our study, we used the immunohistochemical 
method to analyze the expression of Shh, Smo, and 
Gli2 proteins and their alteration in the pathogenesis 
of the nodular type of BCC, which is usually located 
on UV-exposed body areas. We observed significantly 
increased immunoexpression of the Shh and Smo 
proteins in the BCC group, as compared to normal 
controls. Furthermore, the immunoexpression of 
Shh was significantly positively correlated with the 
immunoexpression of Smo in both tested groups. This 
observation testifies to the interaction between them.
In 1999, Michiko et al. [17] published a study de-
scribing the overexpression of Smo mRNA in BCC 
compared with its expression in normal human skin. 
In addition, they observed that Smo mRNA expres-
sion might be associated with the progression of BCC 
tumors, and divided BCCs into two histologic types: 
superficial and nodular. We analyzed the nodular type 
of BCC localized on the face, and our results are in 
line with those of other authors. The study by Xie et 
al. [16] showed direct evidence that mutated Smo can 
function as an oncogene in BCCs, as they observed 
skin abnormalities similar to BCCs that developed in 
transgenic murine skin overexpressing mutant Smo.
Many studies also indicate high levels of ultravio-
let-specific mutations in the SMO gene in groups of 
BCC patients, which confirms its significance in the 
development of BCC, probably by leading to consti-
tutive activation of the protein. Couvé-Privat et al. 
[18] have analyzed the involvement of the SMO gene 
in the genesis of BCC by examining skin tumors from 
patients with xeroderma pigmentosum. On the basis 
of this analysis, they indicated the presence of relati-
vely high levels of Smo proto-oncogene mutations in 
BCCs. Our results also support this hypothesis. 
The significance of the Shh protein in canceroge-
nesis was confirmed in the study of Fan and Khavari 
[19], who indicated that the cell-cycle withdrawal 
normally associated with terminal differentiation is 
blocked in human keratinocytes that overexpress Shh. 
This finding may support our results. 
It is also known that Shh induces features of basal 
keratinocytes into HaCaT organotypic cell cultures. 
Bigelow et al. [20] have demonstrated that Shh in 
HaCaT keratinocytes grown in organotypic cultures 
induced a basal-cell phenotype, as proven by their 
morphology, transepithelial staining of cytokeratin, 
and suprabasilar proliferation. Furthermore, Shh also 
induced keratinocyte infiltration in the underlying 
collagen matrix.
Deregulation of the Shh pathway is associated with 
basal-cell carcinoma (BCC) due to up-regulation of 
the GLI genes (GLI1 and GLI2). The significance of 
the role of the GLI genes in mediating carcinogene-
Table 2. Correlations between immunoexpression of Shh, 
Smo, and Gli2 in basal-cell carcinoma and controls
Pair of variables Basal-cell 
carcinoma
(n = 41)
Control group
(n = 22)
Shh vs. SMO r = 0.49, p < 0.001 r = 0.68, p < 0.02
Shh vs. Gli2 – r = 0.55, p = 0.06 (NS)
Statistical analysis was performed as described in Methods
Table 1. A comparison of semiquantitative and quantitative 
data of Shh, Smo, and Gli2 immunoexpression in basal-cell 
carcinoma and controls
Shh 
(mean score)
Smo 
(mean score)
Gli2 
(%)
Basal-cell 
carcinoma 
(n = 41)
1.67 ± 0.48 1.46 ± 0.4 0.00 ± 0.00
Control group 
(n = 22)
1.17 ± 0.62 0.99 ± 0.39 1.15 ± 0.66
P value p < 0.001 p < 0.001 p = 0.000
The immunoreactivity score for Shh and Smo proteins was obtained as 
described in Methods. Data present mean ±  SD. The percentage of 
cells expressing the Gli2 immunoreactivity was measured as described 
in Methods
Figure 6. Negative Gli2 staining in BCC (A), nuclear sta-
ining for Gli2 in normal epidermis (B). × 400
A B
Figure 5. Negative Gli2 staining in BCC (A), nuclear sta-
ining for Gli2 in normal epidermis (B). × 100
A B
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sis in different structures has been shown by many 
authors.
To date, there are individual data which have led 
to inconsistent results in regard to Gli2 expression in 
skin BCC, perhaps demonstrating variability in the 
selection and numbers of patients and controls, or else 
reflecting the differences of in vivo and in vitro studies 
and results from different populations. In our study, 
the staining for Gli2 in the BCC group was completely 
negative, but Gli2 was detected in the control patients. 
On the contrary, a study by Ikram et al. [21] has shown 
that Gli2 is expressed in normal skin, as well as in BCC 
tumor islands. In 2012, Agyeman et al. [22] published 
a study describing the importance of targeting Gli 
downstream of Smo in the induction of cell death in 
human colon carcinoma cells. The human GLI genes 
have also been shown to act as oncogenes in brain 
tumors, for example medulloblastomas [23]. More re-
cent studies have also concentrated on the correlation 
between the GLI1 and GLI2 genes. Numerous studies 
indicate a positive feedback loop between these, which 
reveals that Gli1 may be a direct target of Gli2. In our 
study, we did not examine these relationships, but we 
additionally analyzed the correlation between Shh and 
Gli2 in the BCC and control groups. We observed in 
controls that the immunoexpression of Shh tended 
to be positively correlated with staining for Gli2, but 
this correlation did not obtain statistical significance. 
Many scientific communications indicate the signi-
ficance of the overexpression of hedgehog signaling 
molecules and their involvement in different types of 
cancer. For example, Tao et al. [24] confirmed that 
Shh signaling is involved in breast ductal changes and 
malignant transformation in triple-negative breast 
cancer. One study has demonstrated that ectopic 
overexpression of Shh induces stromal expansion 
and metaplasia in the adult murine pancreas [25]. 
On the base of laboratory and clinical investigations, 
and our own observations, we can conclude that the 
investigated signaling pathway plays a key role in the 
development of many types of cancer — especially in 
the most common human cancer in the fair-skinned 
population, the nodular type of BCC.
Pharmacological inhibition of Smo or of down-
stream effectors of this pathway could provide an 
effective treatment for BCCs, and perhaps for other 
cancers as well. The discovery of small-molecule an-
tagonists of Shh signaling, such as cyclopamine, has 
opened up exciting new prospects for BCC therapy 
[26–28]. Recent data indicates the role of cyclopamine 
in blocking the growth of UV-induced BCCs in mice. 
Additionally, it is known that this molecule may also 
inhibit the proliferation of BCC murine cell lines [2]. 
One clinical report concerning four patients with BCC 
described the rapid clinical regression of the cancer in 
response to topical cyclopamine versus placebo [29]. 
Other histological and immunohistochemical analy-
sis have reported apoptosis and increased markers 
of differentiation in response to Shh inhibition [30].
In other studies, the potential role of various 
substances has been shown, offering new therapeutic 
targets for the treatment of BCCs. The authors sug-
gest that the possible role of sterols and vitamin D in 
Shh signaling be investigated, but more work needs 
to be done to confirm these results [30]. 
On the basis of our analysis, we observed signifi-
cantly increased immunoexpression of Shh and Smo 
proteins in the BCC group, compared with the normal 
controls. This may be evidence of the significance of 
the Shh pathway in the development of BCC. 
These results allow use to conclude that sonic 
hedgehog pathway dysregulation may play a signi-
ficant role in skin cancerogenesis, leading to BCC 
development. To our knowledge, the expression of 
the sonic hedgehog pathway in BCCs has not been 
evaluated previously in the Polish population, and this 
pathway was considerably up-regulated in the BCCs, 
compared with healthy skin. Moreover, many other 
studies that examined BCCs were self-reported, and 
did not record the body site, while in our study, the 
diagnosis of BCC was confirmed by pathology, and 
only those subjects with BCCs on the upper cheek 
(a site of high solar exposure) were analyzed. A greater 
understanding of the role of the Shh signaling pathway 
impairment in this population may lead to an effec-
tive strategy for the prevention of BCC development 
among the general population.
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